Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Scientists in Cuba have developed a novel vaccine against lung cancer that has shown the potential to improve survival rates among people living with the disease.

The vaccine, chemically known as racotumomab, has been developed in collaboration with scientists from Argentina. Vaxira has been approved in Cuba and Argentina for advanced non-small cell lung cancer (NSCLC).

How Does Vaxira Work?

It helps the immune system recognize and destroy lung cancer cells.

According to the Cuban Embassy in the US, the vaccine "works by mimicking a molecule found on cancer cells but almost entirely absent in healthy human tissue". It also targets tumors with remarkable precision and has very few side effects.

While advanced NSCLC has limited curative options and poor survival rates, clinical trials of Vaxira showed a significant improvement in survival.

Notably, "one-year survival among patients receiving the vaccine nearly doubled compared with the control group," the post said.

"Real-world data shows median survival of up to 24.5 months in maintenance therapy," it added.

Improved Survival And Minimal Side Effects

Importantly, the vaccine has demonstrated minimal side effects and is considered suitable for long-term use.

The embassy described the vaccine as affordable and accessible compared with many immunotherapies.

In 2025, Vaxira also received Cuba's National Technological Innovation Award.

The commercial rollout of Vaxira is being facilitated by the international public-private consortium ReComBio, linking Havana's Center of Molecular Immunology (CIM) with Argentina's Elea Laboratories.

What Is Lung Cancer?

Lung Cancer is one of the most common and serious types of cancer. It is also the leading cause of cancer-related deaths worldwide, with approximately 2.5 million new cases and 1.8 million deaths reported in 2022.

According to the American Cancer Society, lung cancer mainly occurs in older people. Most people diagnosed with lung cancer are 65 or older; a very small number of people diagnosed are younger than 45.

The average age of people when diagnosed is about 70.

It is also the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.

The two main types of lung cancers are:

Non-small-cell lung cancer (NSCLC): This is the most common form, making up about 80–85% of all cases. NSCLC includes three subtypes:

• Squamous cell carcinoma
• Adenocarcinoma
• Large-cell carcinoma

Small-cell lung cancer (SCLC): Less common than NSCLC, this type tends to grow and spread more quickly.

Early Signs and Symptoms to Look Out For

Lung cancer symptoms can mimic less serious conditions, which is why they’re often dismissed or misdiagnosed. If you experience the following symptoms persistently, don’t ignore them—regardless of your age or smoking history:

• Chest pain or discomfort
• Unexplained shortness of breath
• Persistent cough or wheezing
• Shoulder, back, or rib pain
• Fatigue or sudden weight loss
• Blood in sputum (though not always present).

The International Space Station is conducting a very important study as Expedition 74 astronauts are researching how to manufacture large quantities of stem cells for treatment purposes on Earth. Research previously mostly worked on hardware to produce a large amount of stem cells, but now the InSPA-StemCellEX-H2 is trying to produce the cells for medical purposes.

This endeavor will rely on the process called “expansion”, which will use the stem cells from the human body and divide them. Though this is already possible on earth, the quality of created stem cells is far poorer than those from the human body, as it cannot create new cells in the blood, but the ones created in space will solve this problem, which will be crucial in the treatment of leukemia, as they need stem cells in the blood system post-chemotherapy.

Dr. Tobias Niederwieser, assistant research professor at BioServe Space Technologies within the University of Colorado Boulder, says, “The microgravity environment in space is much more suitable for keeping the stem cells in their high-quality state during expansion.” He added, “The result is really to benefit patients in hospitals here on Earth.”

Read Also: Pancreatic Cancer: What Is The Role Of Keratin 17 In Driving The Feared Disease?

What Are The Daily Habits That Can Reduce Cancer Risk?

• Consuming a healthy and balanced diet rich in fruits, vegetables, whole grains, and lean proteins can reduce cancer risk. Berries, nuts, and green leafy vegetables contain many antioxidant properties that are useful in fighting oxidative stress-induced cancer.

• Regular physical activity keeps the body fit and reduces the risk of breast, colon, and endometrial cancers. Participating in moderate exercise for at least 150 minutes per week or 75 minutes of vigorous activity, such as walking, swimming, or yoga.

• Avoid tobacco and cut down on alcohol consumption.

• Skin cancer is one of the most preventable types of cancer. Applying sunscreen with high SPF, finding shade, and avoiding tanning beds would save you from harmful ultraviolet rays.

• Long-term stress can weaken the immune system and may contribute to an increased risk of cancer. Incorporating stress-relief techniques such as mindfulness, practising deep-breathing exercises, and engaging in enjoyable hobbies can enhance overall well-being. Also, having adequate sleep, 7-8 hours of quality sleep each night, aids cellular repair and maintains a robust immune system.

• Exposure to environmental elements like pesticides, pollutants, and workplace chemicals can increase the risk of cancer. To avoid this risk, wearing protective gear, opting for organic produce, and ensuring adequate ventilation in living or working areas can greatly assist.

The White House has announced that US President Donald Trump is in “excellent health”. But doctors flag missing medical details.

Trump, 79, underwent an annual medical examination at the Walter Reed National Military Medical Center on May 26. Shortly after the test that lasted three hours, he shared that “everything checked out perfectly.”

Dr. Sean Barbabella, physician to the president, in a memorandum released late last week, said that “President Trump is demonstrating strong cardiac, pulmonary, neurological, and overall physical function.” He added that Trump is “fully fit to carry out all duties of the Commander-in-Chief and Head of State.”

However, doctors stated that the test results authorized by the President for public release contain notable gaps.

Questions Raised Over Cardiovascular Details

According to experts, the physical examination lacks detailed results from tests used to assess cardiovascular health.

Barbabella’s description of Trump’s cardiac health cites results from a coronary CT angiography, an echocardiogram, and an artificial-intelligence-enhanced electrocardiogram analysis.

Jonathan Reiner, Professor of Medicine and Surgery, Interventional Cardiologist, in a post on social media platform X, questioned the need for another coronary artery CT on Trump, as he was last scanned in October.

"We don’t typically scan patients 6 months later unless we are concerned about a finding on the initial scan. What prompted the repeat CT?" he said.

Further, to fully assess the president’s cardiac health, other doctors said they would want to see a calcium score, a description of any plaque in the arteries, and a CAD-RADS score to assess narrowing in the arteries, The Wall Street Journal reported.

“If I were creating a report to send to another physician, I would have mentioned a little bit more about the carotid ultrasound,” William Shutze, a Texas vascular surgeon, was quoted as saying. “What amount of plaque there is going to be—because almost all of us are going to have some buildup there.”

Also Read: President Donald Trump Remains In Excellent Health, Says White House

Too Good Cholesterol Results

Further, Trump’s cholesterol numbers and medication regimen also attracted attention from physicians who reviewed the memorandum.

According to the report, his HDL (good cholesterol) level was 70 mg/dL, while his LDL (bad cholesterol) level was 53 mg/dL.

The report said Trump takes rosuvastatin and ezetimibe for cholesterol management.

“He’s got like the best cholesterol numbers you’ll see,” said Daniel Torrent, adding that it is unusual for medication alone to achieve such favorable values. “We don’t usually manage people to the point where they’re that good.”

“That report is almost too good to be true for somebody of his age,” Shutze said. “This seems to be a filtered narrative.”

Notably, neurological condition of Trump, the oldest elected as President of America, has remained a subject of serious discussion, with many doctors pointing out that he's suffering from dementia. But the test results revealed him to be in “normal mental status".

Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.

"Why was the president again given a MOCA dementia screening test? He’s had 3 in the recent past," Reiner asked, while also questioning Trump's "more frequent than the traditional yearly exam?"

Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation

White House Responds

“President Trump has publicly released more detailed information about his health than any other president in history—showing he is in excellent health,” White House communications director Steven Cheung said in a written statement.

He criticized outside physicians for speculating about a report for a patient not under their care, the WSJ said.

The White House added that “the absence of discussion regarding a specific medication, dosage, or historical medical condition should not be interpreted as a lack of monitoring or treatment”.